Elena Ratner, MD
Obstetrics & Gynecology · New Haven, CTNPI 1588846463
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,025 of the $8,369 with a category attached, or 72.0%. 6 manufacturers reported payments, led by AstraZeneca at 57.1% of the total. Reporting peaked in 2019 at $7,413 and has fallen 89.5% since, to $781 in 2024. Among obstetrics & gynecology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $418.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Tesaro, Inc.$3K
- Foundation Medicine, Inc.$345
- Genentech USA, Inc.$125
- Clovis Oncology, Inc.$36
- Covidien LP$14
Across 38 payments — averaging $2911.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$76K
- AstraZeneca$18K
- GSK$16K
What the payments were for
- Consulting fees$6,02572%
- Speaking & faculty fees$6508%
- Travel & lodging$90811%
- Food & beverage$7509%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $4,783 |
| Tesaro, Inc. | 6 | $3,066 |
| Foundation Medicine, Inc. | 3 | $345 |
| Genentech USA, Inc. | 1 | $125 |
| Clovis Oncology, Inc. | 1 | $36 |
| Covidien LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$1,925
- FOUNDATIONONE$170
- FOUNDATIONONE HEME$170
- FOUNDATIONONE CDX$170
- FOUNDATIONFOCUS$170
- FOUNDATIONONE LIQUID$170
- Avastin$125
- FOUNDATIONONE LIQUID CDX$108
How this compares
$8,369 in reported general payments places this provider in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 12 | $267 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in New Haven
- Mary MinkinNew Haven$285K
- Alessandro SantinNew Haven$98K
- Randall KaumpNew Haven$16K
- Sangini ShethNew Haven$5K
- Catherine SalvaNew Haven$5K
- Tessa MaddenNew Haven$4K
- Emre SeliNew Haven$4K
- Frederick RauHartford$89K
- Peter AuerbachGroton$41K
- Shieva GhofranyStamford$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.